ECL

Lloyds Bank plc 2022 Q3 Interim Management Statement

Retrieved on: 
Thursday, October 27, 2022
Financial Conduct Authority, ECL, Growth, Group, Movement, Amortization, Income, RCF, RNS, London, Reading, HBOS, UK, COVID-19, United Kingdom, London Stock Exchange, UK Government G-Cloud, Lloyds Banking Group, Commercial bank, Web browser, Reinsurance, Bank, Online gambling

Net interest income was 9,458 million, an increase of 1,209 million compared to 8,249million in the nine months to 30September 2021.

Key Points: 
  • Net interest income was 9,458 million, an increase of 1,209 million compared to 8,249million in the nine months to 30September 2021.
  • Other income was 162million lower at 2,661 million in the nine months to 30 September 2022 compared to 2,823million in the same period last year.
  • Total operating expenses decreased by 131 million to 6,629 million compared to 6,760million in the first nine months of 2021.
  • Total assets were 24,590 million, or 4 per cent, higher at 627,439 million at 30 September 2022 compared to 602,849million at 31December 2021.

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, October 14, 2022
Conference, STI, Hepatitis, FX, Chlamydia, CEO, Operating cost, Public expenditure, DNA, Syphilis, CDC, Biochemistry, New York State Department of Health, Severe acute respiratory syndrome coronavirus 2, DOH, NYSE, Jefferies Group, General counsel, GAAP, Investment, SG, NEW, Center, Company, Industry, Conference call, GLOBE, HPV, FDA, APOE, Growth, Review, COVID-19 testing, Laboratory, Income, EUA, Simplex, Goal, ECL, EBITDA, Internet, Rheumatology, EDX, ENZ, Total, GMP, LDT, Monkeypox, Health, Â, Research, Gonorrhea, ELS, COVID-19, Pharmaceutical industry, Management, Video game, Fine chemical, Vaccine, Reinsurance, Fossil fuel, Enzo, COVID

Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.

Key Points: 
  • Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.
  • Total fourth quarter 2022 revenues were $20.3 million, compared to $24.8 million in the fourth quarter 2021.
  • Consolidated gross margins were 21.4% in the fiscal fourth quarter as compared to 39.5% for the comparable quarter in the previous fiscal year.
  • Enzo Clinical Lab revenue was $12.4 million in the fiscal fourth quarter as compared to $16.8 million in the fourth quarter of 2021.

Ecolab and Siemens Partner to Help Industry Reduce Greenhouse Gas Emissions, Improve Production

Retrieved on: 
Thursday, October 6, 2022
Software, Utilities, Data Management, Sustainability, Alternative Energy, Energy, Technology, Other Manufacturing, Environment, Green Technology, Chemicals, Plastics, Other Technology, Manufacturing, Health, Climate, Efficiency, Digital Enterprise Research Institute, Hygiene, NYSE, Engineering, Carbon, Intelligence, Partnership, Technology, Automation, Industry, DI, ECL, Water, Food safety, CEO, Energy and Climate Intelligence Unit, Food, Solution, CO2, Renewable energy, Ecolab

Ecolab, Inc., and Siemens today announced a strategic partnership that will help customers accelerate their progress toward sustainability and productivity goals.

Key Points: 
  • Ecolab, Inc., and Siemens today announced a strategic partnership that will help customers accelerate their progress toward sustainability and productivity goals.
  • Traditional utility systems are a source of significant greenhouse gas emissions, as water requires substantial energy to heat, cool, move and treat.
  • In 2021, Ecolab helped customers conserve 45 trillion British thermal units of energy and avoid 3.6 million metric tons of greenhouse gas emissions.
  • By 2030, Ecolab aims to help customers become entirely carbon neutral by reducing greenhouse gas emissions by 6 million metric tons annually.

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Retrieved on: 
Tuesday, September 27, 2022
Data, Synthetic biological circuit, Piperacillin/tazobactam, Safety, Meropenem, Clostridioides difficile infection, GI, Infection, Patient, Clinical trial, Form 8-K, Absorption, Washington University School of Medicine, Cohort, Time, IV, Sale, Sepsis, CGMP, Clostridioides, Company, Acquisition, Growth, Washington University School of Law, AES, Annual report, SYN, SEC, HCT, CDI, ECL, NYSE, Risk, Population, VCN, Review, Neoplasm, VRE, SAE, GLOBE, Marketing, Șaeș, Plasma, IAP, Therapy, Cefepime, Washington University in St. Louis, AMR, Private Securities Litigation Reform Act, Maintenance, DSMC, Terminology, Pharmacokinetics, Fever, Degenerative disease, Pharmaceutical industry, Antibiotics

ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the first Cohort of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

Key Points: 
  • A total of 13 SAEs were reported among 10 patients, with the most common SAE being infections and infestations including sepsis.
  • None of the three ECL positive plasma samples were found to contain active SYN-004 using a functional enzyme activity assay.
  • The ongoing randomized, double-blinded, placebo-controlled Phase 1b/2a clinical trial is being conducted at Washington University School of Medicine in St. Louis.
  • A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis.

Darrell Brown Named Ecolab President and COO

Retrieved on: 
Tuesday, September 27, 2022
Other Manufacturing, Technology, Chemicals, Plastics, Other Technology, Manufacturing, Other Health, Health, General Health, Food Tech, Darrell, ECL, NYSE, Knowledge, Inc., Health, Growth, COO, Hygiene, Food safety, Food, Water, Global Industrial, Management, Asia-Pacific, Ecolab

Ecolab Inc. announced that Darrell R. Brown, currently executive vice president and president, Global Industrial, will become president and chief operating officer (COO) effective Oct. 1, 2022.

Key Points: 
  • Ecolab Inc. announced that Darrell R. Brown, currently executive vice president and president, Global Industrial, will become president and chief operating officer (COO) effective Oct. 1, 2022.
  • Brown, 59, has served as executive vice president and president of the Global Industrial group since 2019.
  • Earlier, he was executive vice president and president of Ecolabs Energy Services Division.
  • Darrell joined Ecolab in 2002 and has held several leadership positions within the company, including executive vice president and president, Europe; executive vice president, Asia Pacific; and vice president and general manager for Australia and New Zealand.

Ecolab Schedules Webcast and Conference Call on November 1

Retrieved on: 
Tuesday, September 20, 2022
Health, Chemicals, Plastics, Manufacturing, Commercial Building & Real Estate, Construction & Property, General Health, Building Systems, ECL, Water, Hygiene, Health, Food safety, Webcast, NYSE, Food, Dietary supplement, Pharmaceutical industry, Ecolab

A replay of the webcast and supplemental data will be available on Ecolabs website.

Key Points: 
  • A replay of the webcast and supplemental data will be available on Ecolabs website.
  • A trusted partner at nearly three million customer locations, Ecolab (NYSE: ECL) is the global leader in water, hygiene and infection prevention solutions and services that help protect people, planet and business health.
  • With annual sales of $13 billion and more than 47,000 associates, Ecolab delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, help maintain clean and safe environments, optimize water and energy use, and improve operational efficiencies and sustainability for customers in the food, healthcare, hospitality and industrial markets in more than 170 countries around the world.
  • www.ecolab.com

Ecolab Schedules Webcast of Industry Conference for September 13, 2022

Retrieved on: 
Thursday, September 8, 2022
Finance, Health, Chemicals, Plastics, Professional Services, Food, Beverage, Manufacturing, Retail, Other Health, News, Hygiene, ECL, Food, Webcast, Water, Food safety, Health, Pharmaceutical industry, Ecolab

A replay of the webcast will be available through October 30, 2022.

Key Points: 
  • A replay of the webcast will be available through October 30, 2022.
  • To access the webcast, visit the News and Events section of Ecolabs Investor website at www.ecolab.com/investor and click on the webcast details.
  • A trusted partner at nearly three million customer locations, Ecolab (ECL) is the global leader in water, hygiene and infection prevention solutions and services that help protect people, planet and business health.
  • www.ecolab.com

Ecolab Declares Regular Dividend

Retrieved on: 
Thursday, August 4, 2022
General Health, Manufacturing, Environment, Health, Chemicals, Plastics, Food, ECL, Hygiene, Health, Water, NYSE, Food safety, Holding company, Pharmaceutical industry, Ecolab

The board of directors of Ecolab Inc. today declared a regular quarterly cash dividend of $0.51 per common share, to be paid October 17, 2022 to shareholders of record at the close of business on September 20, 2022.

Key Points: 
  • The board of directors of Ecolab Inc. today declared a regular quarterly cash dividend of $0.51 per common share, to be paid October 17, 2022 to shareholders of record at the close of business on September 20, 2022.
  • Ecolab has paid cash dividends on its common stock for 85 consecutive years.
  • A trusted partner at nearly three million customer locations, Ecolab (NYSE:ECL) is the global leader in water, hygiene and infection prevention solutions and services that help protect people, planet and business health.
  • www.ecolab.com

New Leadership Appointment Enhances Focus on Talent Development, Employee Engagement and Strategic Organizational Design

Retrieved on: 
Thursday, August 4, 2022
Professional Services, Technology, Agriculture, Commercial Building & Real Estate, Natural Resources, Construction & Property, Other Manufacturing, Engineering, Human Resources, Automotive Manufacturing, Landscape, Manufacturing, ECL, Multimedia, Think Small, University, Toro (company), King, NYSE, College, Snow, Growth, Leadership, Lawn-Boy, Hammerhead, Master of Business Administration, Benedictine College, TTC, Snowplow, Education, Acquisition, Trust, Toro, Bachelor of Science in Human Biology, Electronics, CHRO, Cornell University, Maintenance, Business administration, Culture, Golf, Master of Arts in Special Education, Management, Ecolab, Science, X mark

She is an exceptional human resources professional who brings a wealth of experience creating and implementing organizational growth and alignment strategies.

Key Points: 
  • She is an exceptional human resources professional who brings a wealth of experience creating and implementing organizational growth and alignment strategies.
  • Her knowledge of enterprise design and talent development will enable TTC to build upon the successful foundation already in place.
  • I would also like to thank Amy for her outstanding leadership of the human resources team since 2015.
  • During her tenure the organization experienced significant growth and the function implemented several key strategic initiatives and platforms that drove employee engagement, fostered inclusion and diversity and further strengthened TTCs culture.

Ecolab Schedules Webcast of Industry Conference for August 10, 2022

Retrieved on: 
Thursday, July 28, 2022
Food Tech, Chemicals, Plastics, Health, Technology, Manufacturing, Other Health, News, NYSE, Food, Webcast, Health, Water, ECL, Food safety, Hygiene, Pharmaceutical industry, Ecolab

A replay of the webcast will be available through September 30, 2022.

Key Points: 
  • A replay of the webcast will be available through September 30, 2022.
  • To access the webcast, visit the News and Events section of Ecolabs Investor website at www.ecolab.com/investor and click on the webcast details.
  • A trusted partner at nearly three million customer locations, Ecolab (NYSE:ECL) is the global leader in water, hygiene and infection prevention solutions and services that help protect people, planet and business health.
  • www.ecolab.com